Medulloblastoma is a highly malignant, WHO Grade 4 embryonic tumor of the central nervous system that primarily arises in the posterior fossa and cerebellum. Accounting for approximately 20% of pediatric brain tumors, it requires rapid multimodal diagnosis, complete brain and spinal MRI imaging, and integrated surgical, radiation, and chemotherapeutic management.
Medulloblastoma is one of the most common malignant childhood brain tumors, typically arising in the posterior fossa, particularly in the cerebellum. According to the World Health Organization (WHO) classification, medulloblastomas are part of the Embryonal Tumor group and are classified as WHO Grade 4, indicating a highly aggressive tumor with a significant propensity for dissemination. They form a key component of pediatric brain tumors.
Medulloblastomas account for approximately 20% of all pediatric brain tumors. They are rare in adults, often referred to as “medulloblastoma adult” in clinical contexts. This tumor can disseminate through the cerebrospinal fluid (CSF) to both the brain and spinal cord, a process known as drop metastasis, which can lead to leptomeningeal disease.
Histopathological and Molecular Classification of Medulloblastoma
Modern classification integrates both histological and molecular features:
1. Histopathological Subtypes
- Classic Medulloblastoma: Most common subtype. Small, densely packed, round tumor cells with high mitotic activity.
- Desmoplastic / Nodular Medulloblastoma: More frequent in infants under 3 years and in adults. Better prognosis compared to the classic subtype.
- Large Cell / Anaplastic Medulloblastoma: The most aggressive form. High risk of recurrence and CSF dissemination.
2. Molecular Subgroups (WHO 2021)
- WNT-activated Medulloblastoma: Generally the best prognosis. More common in children; low risk of CSF metastasis.
- SHH-activated Medulloblastoma: More common in infants and adults. Prognosis worsens in the presence of TP53 mutations.
- Group 3 Medulloblastoma: Often associated with MYC amplification. Poor prognosis and high likelihood of CSF dissemination.
- Group 4 Medulloblastoma: The most common molecular subtype. Intermediate prognosis.
Symptoms and Clinical Presentation
Due to its posterior fossa location, medulloblastoma frequently leads to hydrocephalus and increased intracranial pressure. The most common symptoms include:
- Headache and morning vomiting: Signs of increased intracranial pressure.
- Gait disturbances and imbalance: Cerebellar ataxia.
- Dizziness
- Blurred or double vision: 6th cranial nerve compression.
- Irritability and cognitive decline: Frequently seen in pediatric patients.
- Back pain and bowel/bladder dysfunction: In cases with spinal drop metastases.
Diagnostic Methods
Medulloblastoma diagnosis relies on a combination of clinical suspicion, imaging, and histopathology. Medulloblastoma radiology:
Magnetic Resonance Imaging (MRI)
Brain MRI shows a posterior fossa mass with contrast enhancement. Complete spinal MRI is strictly required to detect CSF dissemination (drop metastases).
Cerebrospinal Fluid (CSF) Analysis
Performed after surgery to avoid herniation risks or tumor seeding. Detection of malignant cells confirms leptomeningeal spread.
Histopathological and Molecular Testing
Definitive diagnosis is based on surgical resection or biopsy. Molecular subgrouping guides prognosis and therapy selection.
Medulloblastoma Treatment Approaches
Management requires a multidisciplinary team, including pediatric neurosurgery, oncology, and radiation oncology.
1. Microsurgical Resection (Primary Treatment)
Goal: Maximal safe tumor resection. Gross total resection improves prognosis. Functional preservation is critical due to cerebellar and brainstem proximity.
2. Radiotherapy
Standard in children older than 3 years and adults. Craniospinal irradiation (CSI) is performed to eliminate microscopic CSF metastases. Dose reduction is possible in low-risk patients; proton therapy helps spare healthy tissue.
3. Chemotherapy
Common agents include vincristine, cisplatin, lomustine (CCNU), and cyclophosphamide. In infants, intensive chemotherapy is used to delay radiotherapy and reduce long-term neurocognitive side effects. Therapy is personalized based on molecular subgroup and risk status.
The Role of Neuro-Oncology Tumor Boards
Neuro-oncology tumor boards bring together specialists from neurosurgery, oncology, neuroradiology, pathology, endocrinologist and radiation therapy to discuss individual cases. These interdisciplinary meetings enhance treatment planning, foster personalized care, and have been linked to prolonged survival and better quality of life.
Frequently Asked Questions
What is medulloblastoma?
Medulloblastoma is a fast-growing, highly malignant (WHO Grade 4) embryonal brain tumor that originates in the posterior fossa or cerebellum, predominantly affecting pediatric patients.
What are drop metastases in medulloblastoma?
Drop metastases occur when cancer cells detach from the primary tumor in the cerebellum and travel through the cerebrospinal fluid (CSF) to seed along the spinal cord or other parts of the brain.
What are the four molecular subgroups of medulloblastoma?
According to WHO classification, medulloblastoma is divided into WNT-activated (best prognosis), SHH-activated, Group 3 (highest metastatic risk/poor prognosis), and Group 4 (most common).
What are the main symptoms of medulloblastoma?
Common symptoms include morning headaches and vomiting due to obstructive hydrocephalus, unsteadiness or gait ataxia from cerebellar involvement, double vision, and back pain if spinal metastases exist.
How is medulloblastoma treated?
Standard treatment involves maximal safe microsurgical resection, followed by craniospinal irradiation (CSI) and combination chemotherapy tailored to the patient's age and molecular risk group.
Why is radiation therapy often delayed in young infants with medulloblastoma?
Craniospinal radiation can cause severe long-term neurocognitive, endocrine, and developmental side effects in children under 3 years old, so high-dose chemotherapy is used first to delay or avoid radiation.